Efficacy observation of medroxyprogesterone acetate in treatment of atypical endometrial hyperplasia / 中国生化药物杂志

ABSTRACT

Objective To investigate the clinical efficacy and safety of medroxyprogesterone acetate in the treatment of endometrial atypical hyperplasia patients.Methods 98 cases of endometrial atypical hyperplasia patients were randomly divided into study group and control group with 49 cases in each group, study group were treated with medroxyprogesterone acetate treatment, and control group were given estradiol valerate tablets treatment.Two groups of patients were treated for 3 ~6 menstrual cycles, and clinical curative effect of two groups was compared.Results After treatment, the PBAC score and endometrial thickness inspection results in study group and control group respectively decreased significantly compared with before treatment (P<0.05), and the above indexes in study group were significantly lower than control group (P<0.05).After treatment, the hemoglobin value in two groups at 1st, 2nd, 3rd month after treatment was significantly higher than before treatment (P<0.05), and hemoglobin values at 1st, 2nd month after treatment was significantly higher than control group (P<0.05).The effective rate of study group (95.92%) was significantly higher than that of control group (81.63%, P<0.05).The recurrence rate during six months was 4.08% in study group, 8.16% in control group, and the difference was not statistically significant.Conclusion The efficacy of medroxyprogesterone acetate is better than estradiol valerate tablets in the treatment of endometrial atypical hyperplasia patients, which is safe and effective.